ScholarLens Back to search
2006•Annals of the Rheumatic DiseasesOpen access

Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects

Florenzo Iannone, Francesco Trotta, C. Monteccuco, Roberto Giacomelli, Mauro Galeazzi, Marco Matucci‐Cerinic, Clodoveo Ferri, Maurizio Cutolo, Lisa Maria Bambara, G Triolo, Gianfranco Ferraccioli, Gabriele Valentini, Giovanni Lapadula

Open full text 55 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

Open-access reader

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 55 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Infliximab, Etanercept, Medicine, Rheumatoid arthritis, Erythrocyte sedimentation rate, Internal medicine, Adverse effect, Visual analogue scale

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects — Research Paper | ScholarLens